Safety of Immunogenicity Testing of a Pilot Polysaccharide Vaccine Preparation to Pseudomonas aeruginosa.
Annual rept. 16 Aug 79-15 Aug 80,
PETER BENT BRIGHAM HOSPITAL BOSTON MA
Pagination or Media Count:
The scope of this contract included preparation and testing of a pilot vaccine to Pseudomonas aeruginosa infections up to the human trial stage, development of assays for measuring the antibody response of immunized and infected individuals, testing of the immunogenicity of the vaccine product in animals, assessment of the material in compromised animal host models as a protective agent, assessment of cell mediated protective mechanisms induced by the vaccine, including in vitro cellular studies, determinations of the genetic basis of response to the vaccine in inbred mouse strains, and assessment of the role of lipopolysaccharide LPS as an immunogenic or biologically active component of the vaccine. The vaccine is a high molecular weight polysaccharide PS material isolated from the outer cell surface or cultural supernates of P. aeruginosa 1. Similar types of polysaccharides have been shown to be effective vaccines for a number of bacterial infections, such as meningitis cause by Neisseria meningitidis and pneumonia caused by Streptococcus pneumoniae.
- Medicine and Medical Research